Literature DB >> 34269283

A rare case of vena cava leiomyoma: A case report.

Gabriel H Sánchez1, Mauricio Abello2, Enrique J Osorio2, Juan F Muriel2.   

Abstract

Intravascular leiomyoma is an uncommon disease and depending of vascular involvement and anesthetic challenge. We review a case of a 53-year-old woman who underwent vena cava leiomyoma resection under cardiopulmonary bypass using deep hypothermic circulatory arrest (DHCA). Invasive hemodynamic and neurologic monitoring, transesophageal echocardiography, and viscoelastic coagulation test were used during the procedure. Total surgical resection was accomplished with no complications and the patient was extubated 2 days after surgery without cardiac or neurologic deficit. Although uncommon, level IV intravascular leiomyoma surgery is a challenge because the total resection needs DHCA, prolonged cardiopulmonary bypass and aortic cross-clamp times. These conditions expose the patient to the risk of coagulopathy, low cardiac output syndrome, and neurologic deficit.

Entities:  

Keywords:  Deep hypothermic circulatory arrest; Mayo classification; intravascular leiomyoma

Mesh:

Year:  2021        PMID: 34269283      PMCID: PMC8404577          DOI: 10.4103/aca.ACA_128_19

Source DB:  PubMed          Journal:  Ann Card Anaesth        ISSN: 0971-9784


  10 in total

1.  Anesthetic management of renal cell carcinoma with inferior vena caval extension.

Authors:  F Chan; W D Ngan Kee; J M Low
Journal:  J Clin Anesth       Date:  2001-12       Impact factor: 9.452

Review 2.  Intravenous leiomyomatosis extending into the right ventricle after subtotal hysterectomy.

Authors:  Mehmet Sah Topcuoglu; Hafize Yaliniz; Hakan Poyrazoglu; Acar Tokcan; Süleyman Cansun Demir; Abdi Bozkurt; Handan Zeren
Journal:  Ann Thorac Surg       Date:  2004-07       Impact factor: 4.330

3.  Perioperative anesthetic management for renal cell carcinoma with vena caval thrombus extending into the right atrium: case series.

Authors:  Yoshihisa Morita; Kengo Ayabe; Michael Nurok; Jerry Young
Journal:  J Clin Anesth       Date:  2016-11-17       Impact factor: 9.452

4.  TEE in the diagnosis of intravenous leiomyomatosis extending into the right atrium.

Authors:  L A Podolsky; L E Jacobs; A Ioli; M N Kotler
Journal:  Am Heart J       Date:  1993-05       Impact factor: 4.749

Review 5.  Intracardiac Extension of Intravenous Leiomyomatosis.

Authors:  Jonathan D Price; Constantine Anagnostopoulos; Alan Benvenisty; Ravi K Kothuru; Sandhya K Balaram
Journal:  Ann Thorac Surg       Date:  2017-02       Impact factor: 4.330

6.  Reversible tricuspid valve obstruction during removal of renal cell carcinoma with intracardiac tumor extension.

Authors:  K Takeda; S Sawamura; H Tamai; R Hagihara; K Hanaoka
Journal:  Anesth Analg       Date:  2000-11       Impact factor: 5.108

Review 7.  Cavoatrial tumor thrombus: single-stage surgical approach with profound hypothermia and circulatory arrest, including a review of the literature.

Authors:  Bruno Chiappini; Carlo Savini; Giuseppe Marinelli; Sofia Martin Suarez; Marco Di Eusanio; Vinicio Fiorani; Angelo Pierangeli
Journal:  J Thorac Cardiovasc Surg       Date:  2002-10       Impact factor: 5.209

8.  The dose-response relationship of tranexamic acid.

Authors:  J C Horrow; D F Van Riper; M D Strong; K E Grunewald; J L Parmet
Journal:  Anesthesiology       Date:  1995-02       Impact factor: 7.892

9.  Intravenous leiomyomatosis with inferior vena cava or intracardiac extension and concurrent bilateral multiple pulmonary nodules: A report of 2 cases.

Authors:  Guorui Zhang; Xin Yu; Jinghe Lang
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 10.  Massive pelvic recurrence of uterine leiomyomatosis with intracaval-intracardiac extension: video case report and literature review.

Authors:  Lidia Castagneto Gissey; Germano Mariano; Layla Musleh; Pasquale Lepiane; Marco Colasanti; Roberto L Meniconi; Federico Ranocchi; Francesco Musumeci; Mario Antonini; Giuseppe M Ettorre
Journal:  BMC Surg       Date:  2017-11-29       Impact factor: 2.102

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.